Iron in The Brain Might Help Explain Curious Link Between ADHD And Dementia
Older adults with ADHD are at higher risk of age-related dementias like Alzheimer's disease, and an international team of neuroscientists has found a lead on why this might be the case.
Led by medical physicist Jatta Berberat from the University of Geneva, the team has discovered that iron is distributed similarly in the brains of people with these associated disorders, which may help to explain the link.
There's good evidence that as the human brain ages, it continuously accumulates iron, in both the neocortex (which accounts for about 90 percent of our cerebral cortex) and in the quarter of our brain that sits below the cortex, including the hippocampus, the cerebellum, the amygdala and the basal ganglia.
"Excess iron in certain regions of the brain is often observed [in neurodegenerative diseases] and is associated with increased oxidative stress that furthers neuronal degeneration," explains psychiatrist Paul Unschuld from Geneva University Hospitals.
When iron levels build up in these regions, cognitive performance drops. Quite a few studies have found people with neurodegenerative diseases, including Huntington's, Parkinson's, and Alzheimer's, have noticeably high levels of brain iron, which, because of its magnetic properties, can quite easily be detected by MRI scanners.
The team used this technique to map the layout of accumulated iron in the brains of 32 adults with ADHD, and 29 others without the condition.
The team also took blood samples to measure neurofilament light chain protein (NfL) levels, a protein released when axons are damaged or degenerate. At high levels in blood, NfL indicates damage to the neuronal axons that carry information to neighbouring nerves, and is a potential biomarker for dementia.
Finally, study participants answered questions related to ADHD symptoms and lifestyle factors.
Each facet of this small study was designed to pick up on patterns that may distinguish an ADHD brain by its iron, and look for an association with neuronal axon damage signifying neurodegeneration to indicate whether scientists should pursue this track further.
The MRI-based maps suggest this is no dead end. Participants with ADHD had a distinct distribution of brain iron, with particularly elevated levels in the precentral cortex and a number of other regions. The iron landscape of ADHD brains was different enough from the non-ADHD group to be considered significant.
The researchers also found a significant association between raised iron levels in the precentral cortex of ADHD participants, and NfL levels in their blood. This could mean a build-up of brain iron deposits is creating a communication break-down in the area of the brain responsible for pulling the strings on the rest of the body.
Of the ADHD participants, 19 were taking regular medication for the condition, either methylphenidate (Ritalin) or dexamphetamine.
Some scientists suspect long-term use of psychostimulant medications like these could be behind the ADHD dementia link, because recreational stimulant drugs like MDMA and cocaine are known to affect brain iron levels. Other studies suggest ADHD medication may normalize brain iron in people with ADHD, but long-term effects remain unclear.
Unfortunately, this particular study is too small (and was not designed) to tell us if ADHD medications are actively involved in the tangle of associations, or if they're just innocent bystanders trying to help.
Nonetheless, Unschuld hopes the findings will lead to targeted dementia risk reduction strategies for people diagnosed with ADHD later in life.
"This is especially important since there is a well-known correlation between lifestyle and altered iron levels in the brain," he says.
"To achieve this, additional longitudinal studies are required in order to determine if a reduction of iron levels in the brain is a potential treatment pathway for preventing dementia at an advanced age in persons with ADHD."
This research was published in Psychiatry and Clinical Neurosciences.
Measles Devastates Your Body in a Variety of Ways. Here's What's at Risk.
Vitamin D Could Be an Effective Way to Slow Progress of MS
Protein That Calms Waking Hair Follicles Could Lead to Alopecia Treatment
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS
SUZHOU, China, June 2, 2025 /PRNewswire/ -- XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell therapies. To date, the company has received seven Investigational New Drug (IND) approvals for registered clinical trials from both the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA). All approvals focus on clinical-grade, off-the-shelf and allogeneic iPSC-derived cell therapy candidates targeting central nervous system (CNS) diseases with significant unmet medical needs, including: Parkinson's Disease (PD), the world's second most prevalent neurodegenerative disease affecting over 10 million patients globally (Phase I clinical trials in both China and the U.S.); Spinal Cord Injury (SCI), a major CNS disease impacting more than 10 million patients globally (First-in-Class; Phase I clinical trials in China and the U.S.); and Amyotrophic lateral sclerosis (ALS), a devastating rare neurodegenerative disease (First-in-Class; Phase I/II clinical trial in China and Phase I in the U.S.; designated as an Orphan Drug by the U.S. FDA). XellSmart has completed multiple cases of iPSC-derived dopaminergic neural progenitor cell therapy for patients with Parkinson's disease, including"the first case"in China. This clinical study was approved by the National Health Commission (NHC) of China. In the clinical study, clinical-grade iPSC-derived dopaminergic neural progenitor cells were transplanted into the putamen of the striatum in patients with moderate to advanced Parkinson's disease. With follow-up periods exceeding 12 months, no cell therapy-related adverse events have been observed. Multiple patients showed significant improvements in key efficacy indicators, including"on/off"time duration and MDS-UPDRS scores, as well as notable enhancements in non-motor symptoms. XellSmart is committed to developing clinical-grade, off-the-shelf allogeneic iPSC-derived cell therapies targeting central nervous system (CNS) diseases with no effective treatment options. XellSmart is at the forefront of advancing innovative iPSC-based therapies to address major and intractable CNS disorders:In 2023, China's first iPSC-derived cell therapy (XS228 injection), developed by XellSmart, was granted by FDA as Orphan Drug Designation (ODD) for the treatment of amyotrophic lateral sclerosis (ALS). In 2024, China's first national-level registered clinical study of an iPSC-derived cell therapy for Parkinson's disease—also developed by XellSmart—was approved and initiated, including the first case treated in China. In 2024, the world's first national-level registered clinical study of a subtype-specific iPSC-derived neural progenitor cell therapy (XS228 injection) for ALS was approved. Multiple patients, including the world's first ALS case treated with this approach, received therapy with good safety profiles and preliminary data showing slowed disease progression. In 2025, China's first registrational Phase I clinical trial of an off-the-shelf allogeneic iPSC-derived dopaminergic neural progenitor cell therapy (XS411 injection) for Parkinson's disease was launched, led by the National Neurological Disease Medical Center at Beijing Tiantan Hospital. In 2025, China's first randomized, double-blind, controlled Phase I/II clinical trial of XS411 injection was initiated to treat early-onset Parkinson's disease (EOPD), led by Huashan Hospital of Fudan University, a National Neurological Disease Medical Center. In 2025, the world's first registrational Phase I clinical trial of an off-the-shelf, allogeneic iPSC-derived subtype-specific neural progenitor cell therapy was launched by The Third Affiliated Hospital of Sun Yat-sen University, targeting spinal cord injury (SCI) — a major neurological disorder with no effective treatment. In 2025, the world's first Phase I/II registrational clinical trial of XS228 injection—an off-the-shelf, allogeneic iPSC-derived subtype-specific neural progenitor cell therapy—was initiated by Peking University Third Hospital, targeting ALS, a devastating rare neurodegenerative disease. XellSmart has established a fully dedicated, internationally competitive "All-In" team focusing on development of clinical-grade, allogeneic, off-the-shelf iPSC-derived cell therapies for central nervous system (CNS) diseases that currently lack effective treatment options. XellSmart has built a portfolio of proprietary, globally leading industrial technologies and platforms, fueling sustained in-house innovation centered on its core business. To develop iPSC-derived cell therapy candidates, XellSmart has established and operates an R&D center, a B+ and A-grade GMP manufacturing facility, and a quality control center spanning over 5,000 square meters. Multiple clinical-grade iPSC-derived cell therapy candidates developed by XellSmart have completed core CMC development, with fully integrated clinical-grade manufacturing processes and quality control systems in place. XellSmart has successfully produced clinical batches of multiple GMP-grade iPSC-derived subtype-specific neural progenitor cell therapies, currently deployed in multiple clinical trials. XellSmart has secured multiple rounds of financing, collectively led by renowned market-driven venture capital firms including Qiming Venture Partners, Eli Lilly Asia Ventures, Sequoia Capital China (Hongshan), and others. View original content: SOURCE XellSmart Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Red Sox' Justin Slaten describes shoulder injury, gives timeline for return
ATLANTA — The Red Sox bullpen took another hit Sunday, but the team is hopeful Justin Slaten's shoulder injury won't be a long-term thing. Boston placed Slaten on the 15-day injured list, retroactive to May 29, with right shoulder inflammation and recalled Luis Guerrero from the WooSox to take his place. Slaten hasn't pitched since Wednesday in Milwaukee. He described his IL stint, which can expire as soon as May 13, as precautionary. Advertisement 'Having a little bit of fatigue right now,' Slaten said. 'Don't think it's anything super serious but had some stuff nagging for a little bit now and it caught up to me that last little bit in Milwaukee. It's just a matter of getting ahead of it, taking care of it before something major could happen.' Slaten felt tiredness in his shoulder at different points in the last week and took notice of his velocity dropping in his outing Wednesday. His fastball, which has averaged 97 mph this year, was at 95.6 mph. The Red Sox were hopeful two days of rest would help him rebound, but the issue didn't abate. 'He has been grinding through it,' said manager Alex Cora. 'We gave him two days and yesterday he tried to play catch. He wasn't responding well and we have to protect him. Hopefully, something that he can come back right on time when the days are done. But obviously, we're gonna miss him.' As a rookie in 2024, Slaten missed more than a month in July and August with a forearm/elbow issue that he tried to pitch through. This time, he alerted team trainers to his shoulder soreness early in the process, allowing the club to get its arms around how to attack it. Slaten did not have an MRI. Advertisement 'Last year, I had some similar stuff where something had popped up but I didn't feel like it was necessarily affecting the performance,' Slaten said. 'It was more of a management thing. Eventually, it caught up and bit me in the ass so I think this is a matter of the same thing. 'Last year, I ended up missing a little over a month when we didn't think it was that serious. I think we're pretty confident this 15-day stint on the IL will give it plenty of time to calm down and I'll be fine.' With Boston's rotaton scuffling, Cora went to his bullpen early and often throughout May. Slaten, the primary setup man for closer Aroldis Chapman, pitched 13 innings over 12 games in the month, last pitching on back-to-back days Tuesday and Wednesday in losses to the Brewers. With Slaten and veteran Liam Hendriks (hernia-related issues) both now on the IL and Guerrero and Nick Burdi both called up, the group looks different than it did a week ago. Cora identified lefty Justin Wilson and righties Greg Weissert and Garrett Whitlock as eighth-inning options in Slaten's absence. Slaten has pitched well for Boston outside of a couple blow-up outings. He owns a 3.47 ERA (and 3.17 FIP) while striking out 16 batters in 23 ⅓ innings over 24 games. He had a string of 10 straight scoreless appearances dating back to May 4. More Red Sox coverage Read the original article on MassLive.
Yahoo
4 hours ago
- Yahoo
Detroit Lions center Frank Ragnow retires after 7 seasons, 4 Pro Bowls
DETROIT (AP) — Detroit center Frank Ragnow, a four-time Pro Bowl selection who was key to coach Dan Campbell's Lions revival, announced his retirement from the NFL on Monday after seven seasons. Ragnow, 29, posted to social media that he has tried to convince himself he's feeling well enough to play, 'but I'm not,' he said. Advertisement 'I have given this team everything I have and I thought I had more to give, but the reality is I simply don't,' said Ragnow, who was drafted 20th by the Lions in 2018. 'I have to listen to my body and this has been one of the hardest decisions of my life.' Ragnow battled through multiple injuries during his career. In 2021, following a season in which he played with a fractured throat, general manager Brad Holmes made him the league's highest paid center at the time with a $54 million, four-year extension. Ragnow earned second-team All-Pro honors in 2020, 2023 and 2024. He was selected to his first Pro Bowl in 2020 under then-coach Matt Patricia, and then made three straight from 2022-24. 'These past couple of months have been very trying as I've come to the realization that my football journey is ending and I'm officially retiring from the NFL," Ragnow said. "The Lions organization has been absolutely incredible throughout this process and I can't emphasize this enough how grateful I am for this team and all the fans. It was an absolute honor going to battle for you all.' Advertisement Harrison Phillips, the eighth-year veteran defensive tackle with division rival Minnesota, raved about Ragnow when asked on Monday about the news of his retirement. 'He's one of the best centers I've ever had the privilege to play against,' Phillips said. 'I know that every time I had to play against him, I had to buckle my chinstrap extra tight and watch a lot of extra film.' Phillips said his teammates on the Vikings' offensive line would often ask him for tips about Ragnow's technique because his fundamental blocking skills were so exceptional. 'The way that he played was acknowledged amongst all players on both sides of the line of scrimmage,' Phillips said. ___ AP NFL: The Associated Press